Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: DynaGen

  • News

Executive Summary

DynaGen: Acquires Alpharma subsidiary Able Labs, Cambridge, Mass.-based firm announces Aug. 12. DynaGen is paying $550,000 in cash for the business; Able had $2.5 mil. in 1995 revenues and operated at a loss. DynaGen will acquire rights to 10 approved tablet and suppository ANDA products, a 46,000 sq. ft. manufacturing facility in South Plainfield, N.J. and 45 employees. DynaGen plans to establish a multi-source and specialty pharmaceutical division. It is developing NicErase sublingual lobeline for smoking cessation and anticipates the Able acquisition would provide manufacturing for the product. DynaGen will have $9 mil. in cash after the acquisition...

Table

View full table

Tags:
Latest Headlines

US FDA Developing Model Master File System To Grow Modeling, Simulation Field

US FDA May User Fee Preview: Vaccines, Gene Therapy, And Double Oncologics

Pharma’s IRA Complaints Find Sympathetic Ear In US Appeals Court But Near-Term Relief Unlikely

UK MHRA Considers New Approach To Support Sponsors Throughout Clinical Trial Lifecycle

See All
UsernamePublicRestriction

Register

PS028712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By